Sangamo Biosciences Names Interim CFO After Officer Departure

An announcement from Sangamo Biosciences ( (SGMO) ) is now available.

On February 2, 2026, Sangamo Biosciences’ principal financial officer, Prathyusha Duraibabu, departed the company, and effective February 3, 2026, Vice President of Finance and Corporate Controller, and current principal accounting officer, Nikunj Jain, was appointed Interim Chief Financial Officer and designated as the company’s new principal financial officer. The company emphasized that Jain’s appointment involved no special arrangements, family relationships, or related-party transactions, and that he will not receive additional compensation beyond his existing pay package, underscoring a straightforward and low-disruption leadership transition in the finance function for stakeholders.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Spark’s Take on SGMO Stock

According to Spark, TipRanks’ AI Analyst, SGMO is a Neutral.

The score is held down primarily by weak financial performance: sharply lower revenue, ongoing losses and cash burn, and a weakened equity/leverage profile. Technicals are mixed (short-term improvement but longer-term downtrend), valuation remains constrained by negative earnings, while the earnings call provides a notable offset due to encouraging clinical/FDA updates and a modestly improved cash runway despite continued funding risk.

To see Spark’s full report on SGMO stock, click here.

More about Sangamo Biosciences

Sangamo Biosciences operates in the biotechnology and biopharmaceutical industry, focusing on developing genomic medicine therapies using technologies such as gene regulation and gene editing to address serious unmet medical needs.

Average Trading Volume: 6,638,442

Technical Sentiment Signal: Sell

Current Market Cap: $180.2M

See more insights into SGMO stock on TipRanks’ Stock Analysis page.